Lopimune Tablets IP About
Experience a last chance to secure Lopimune Tablets IP at an unbeatable price-the lowest in the market. This prime, top-ranking antiviral tablet, expertly formulated and marketed by Cipla Ltd, is a noteworthy solution for managing HIV-1 infection. Each yellowish-orange, oval, film-coated tablet contains Lopinavir 200 mg and Ritonavir 50 mg, ensuring consistent efficacy. Encased in a safe HDPE bottle, its prescription-only status ensures proper guidance and usage. Quality-assured with IP grade standards and an assay of NMT 98%-102%, Lopimune is a leading choice for healthcare professionals and exporters in India.
Lopimune Tablets IP: Uses, Benefits & Competitive Edge
Lopimune Tablets IP, designed for oral administration, offer prime support in HIV-1 infection management. With its reliable salt composition of Lopinavir 200 mg and Ritonavir 50 mg, this medicine effectively restrains viral proliferation. The tablet's noteworthy IP grade and strict assay parameters amplify treatment confidence. Clinicians and patients benefit from its film coating and stable formulation, making it a top-ranking antiviral solution well-suited for both local and export needs. Its 24-month shelf life provides application longevity and stock reliability.
Lopimune Tablets IP: Samples, Packaging & Delivery Insights
Secure shipping options are available for Lopimune Tablets IP samples, ensuring prime condition upon arrival. The HDPE bottle packaging, each containing 60 tablets, is designed for robust protection and convenience. Sample requests are welcomed to help clients assess quality before significant expenditure or outlay. With efficient logistics and a dedicated exporter network in India, delivery times are minimized, offering clients prompt access to quality antiviral medication for dependable therapeutic application.
FAQ's of Lopimune Tablets IP:
Q: How should Lopimune Tablets IP be administered for optimal results?
A: Lopimune Tablets IP are intended for oral use and must be taken exactly as prescribed by a healthcare professional to ensure the best outcomes in HIV-1 infection management.
Q: What is the primary benefit of using the top-ranking Lopimune Tablets IP?
A: The key benefit of Lopimune Tablets IP is its proven efficacy in controlling HIV-1 infection, combining Lopinavir and Ritonavir for enhanced antiviral action while meeting high IP grade standards.
Q: When should patients start using Lopimune Tablets IP?
A: Patients should begin taking Lopimune Tablets IP upon diagnosis and prescription from a qualified physician, as prompt intervention improves treatment effectiveness.
Q: Where can I find secure packaging and reliable delivery for Lopimune Tablets IP?
A: Lopimune Tablets IP are securely packaged in HDPE bottles and delivered through trusted exporter and supplier networks in India, ensuring both safety and punctual access.
Q: What is the process for obtaining a sample of Lopimune Tablets IP?
A: Samples of Lopimune Tablets IP can be requested through authorized exporters or suppliers, allowing quality assessment prior to a substantial outlay or order commitment.